115 completed, 69 unknown, 36 recruiting, 22 terminated. 108 Phase 2, 73 Phase 1, 59 Phase 3, 33 Not applicable.
Follow Cancer Research UK: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy - Prostate Cancer, mHSPC | Phase 3 | Recruiting | University College, London | 1500 | 2026-08-28 | 2026-10-16 |
| Using Patient Navigation to Promote Bowel Screening in AAA Attendees. Patient Navigation conversation - Bowel Cancer Screening | Not applicable | Not yet recruiting | University of Surrey | 4190 | 2026-08-03 | 2026-07-23 |
| Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level Daratumumab, Lenalidomide, Dexamethasone - Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) | Phase 3 | Recruiting | University of Leeds | 1226 | 2026-07-01 | 2026-07-15 |
| DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2026-04-01 | 2026-08-17 |
| Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors Tirzepatide - Colorectal Cancer Prevention, Colorectal Adenoma | Phase 1 | Recruiting | Massachusetts General Hospital | 20 | 2026-02-24 | 2026-02-27 |
| Cancer Loyalty Card Study 2 (CLOCS-2) Cases & Controls - Pancreatic Cancer, Colon Cancer | Recruiting | Imperial College London | 2900 | 2026-02-04 | 2026-03-25 | |
| Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE) Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cells - Rhabdomyosarcoma, Ewing Sarcoma | Phase 1 | Recruiting | Children's National Research Institute | 18 | 2026-01-27 | 2026-08-13 |
| 5G-PEARL: Paxalisib in Malignant Brain Tumours Paxalisib, Temozolomide capsule - Malignant Primary Gliomas, Glioblastoma Multiforme (GBM) | Phase 1 / Phase 2 | Recruiting | Institute of Cancer Research, United Kingdom | 64 | 2026-01-19 | 2026-02-05 |
| Healthspan Connect Programme of Research Cancer, Mental Health | Not yet recruiting | King's College London | 100000 | 2026-01-05 | 2025-10-07 | |
| The EAT-FIBRE Study. Modified EatWell diet, EatWell diet - Microbiome Related Mechanisms Linked to Early Onset Colorectal Cancer | Not applicable | Not yet recruiting | King's College London | 200 | 2026-01-01 | 2026-01-07 |
| DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers. Entrectinib - Haematological Malignancy, Malignancy | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2025-11-30 | 2025-11-24 |
| Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery Biosample collection - Oesophageal Adenocarcinoma, Gastric Adenocarcinoma | Recruiting | Imperial College London | 100 | 2025-02-01 | 2025-02-19 | |
| DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations Capmatinib - Solid Tumour, Haematological Malignancy | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2024-11-19 | 2025-11-24 |
| 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours Avutometinib, Defactinib, Temozolomide - Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma) | Phase 1 / Phase 2 | Recruiting | Institute of Cancer Research, United Kingdom | 182 | 2024-11-15 | 2026-01-21 |
| 5G-EMERALD: Amivantamab in Malignant Brain Tumours Amivantamab - Malignant Primary Gliomas, Glioblastoma Multiform (Grade IV Astrocytoma) | Phase 1 | Active not recruiting | Institute of Cancer Research, United Kingdom | 12 | 2024-10-09 | 2026-08-17 |
| Personalized Medicine for Advanced Biliary Cancer Patients Futibatinib, Ivosidenib, Zanidatamab - Biliary Tract Neoplasms | Phase 3 | Recruiting | UNICANCER | 800 | 2024-07-18 | 2026-05-19 |
| A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer UCB4594 - Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck | Phase 1 / Phase 2 | Recruiting | Cancer Research UK | 167 | 2024-07-09 | 2026-05-08 |
| A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer Stereotactic Ablative Body Radiotherapy (SABR), 177Lu-PSMA-617, Androgen Deprivation Therapy (ADT) - Prostate Cancer Metastatic | Phase 3 | Recruiting | University College, London | 3360 | 2024-06-11 | 2025-09-26 |
| A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma Odronextamab, Loncastuximab tesirine, Rituximab - B-cell Non Hodgkin Lymphoma | Phase 2 / Phase 3 | Recruiting | University of Birmingham | 210 | 2024-05-02 | 2026-02-20 |
| A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia Pembrolizumab - Gestational Trophoblastic Disease, Gestational Trophoblastic Neoplasia | Phase 2 | Unknown | Imperial College London | 20 | 2024-02-14 | 2024-04-17 |
Showing 20 of 275. Sign in to see all of them.
Neoplasms (42) · Carcinoma, Non-Small-Cell Lung (25) · Breast Neoplasms (24) · Pancreatic Neoplasms (23) · Lymphoma (21) · Ovarian Neoplasms (21) · Colorectal Neoplasms (19) · Lung Neoplasms (17) · Prostatic Neoplasms (17) · Esophageal Neoplasms (14) · Neoplasm Metastasis (11) · Melanoma (9) · Stomach Neoplasms (9) · Carcinoma, Ovarian Epithelial (8) · Hematologic Neoplasms (8)
Cisplatin (22) · Cyclophosphamide (17) · Carboplatin (16) · Radiotherapy (16) · Gemcitabine (15) · Paclitaxel (12) · Rituximab (11) · Capecitabine (10) · Vincristine (9) · Amplified Fragment Length Polymorphism Analysis (8) · Doxorubicin (7) · Etoposide (7) · Fluorouracil (7) · Leucovorin (7) · Oxaliplatin (7)
United Kingdom (252) · United States (13) · Belgium (10) · Netherlands (10) · Australia (9) · France (9) · Denmark (7) · Ireland (7) · Italy (7) · Austria (6) · Germany (6) · New Zealand (5) · Spain (5) · Sweden (5) · Switzerland (4)
Matthew Krebs, Dr (7) · Paul Pharoah, MD (7) · Adrian L. Harris, MD (4) · Juanita Lopez, MD, PhD (3) · Rosalind A Eeles, FRCP FRCR (3) · Ellie Barnes (2) · Geoffrey Higgins (2) · Jack Cuzick, PhD (2) · Johann de Bono, Prof (2) · Karl Peggs, MD (2) · Martin Forster (2) · Peter J. Hoskin, MD (2) · Roderick Johnson, MD (2) · Simon Rule, MD (2)
PMID 37185961, PMID 12799625, PMID 15928663, PMID 15961763, PMID 18358928, PMID 19008269, PMID 19282241, PMID 19387077, PMID 19554377, PMID 19858379, PMID 19875337, PMID 20683637, PMID 20840664, PMID 21147030, PMID 21231927, PMID 21353720, PMID 21797111, PMID 22014897, PMID 22235096, PMID 22314329, PMID 23108952, PMID 24120480, PMID 24369114, PMID 24484606, PMID 24602760, PMID 24718885, PMID 24879829, PMID 25070546, PMID 25349296, PMID 25415228, PMID 25589626, PMID 25595936, PMID 25775024, PMID 25880814, PMID 25957999, PMID 25964255, PMID 26228433, PMID 26342674, PMID 26493588, PMID 26611473, PMID 26707054, PMID 27025186, PMID 27084277, PMID 27332902, PMID 27397040, PMID 27584578, PMID 28144789, PMID 28163000, PMID 28335886, PMID 28362511
2009 (6), 2014 (6), 2008 (5), 2016 (5), 2015 (4), 1OT2CA297289-01 (1), 1OT2CA297680-01 (1), 2018 (1), 2019 (1), OT2CA278691 (1), U10CA180821 (1)